Data regarding the efficacy of treatment with ibrutinib-rituximab, as compared with standard chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab, in patients with previously untreated chronic lymphocytic leukemia (CLL) have been limited.
hronic lymphocytic leukemia (CLL) is one of the most common lymphoid cancers, accounting for approximately 11% of hematologic neoplasms. A marked improvement in progression-free survival and overall survival among patients with CLL has been realized with the addition of anti-CD20 monoclonal antibodies to purine nucleoside analogue or alkylator-based chemotherapy. 1,2 Phase 3 trials have established the chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as the standard first-line treatment for patients with CLL who are 70 years of age or younger and who are suitable candidates for such therapy after consideration of organ function and side-effect risks. 1, 3 The fludarabine-cyclophosphamide-rituximab combination appears to be particularly effective in patients with immunoglobulin heavy-chain variable region (IGHV)mutated CLL, with roughly half the patients in that subgroup remaining free from progression up to 8 years after initial treatment. [4] [5] [6] [7] Although fludarabine-cyclophosphamide-rituximab therapy is efficacious, it is associated with substantial toxic effects, including severe myelosuppression, a small risk of treatment-related myelodysplasia, and infectious complications, including opportunistic infections due to T-cell immunosuppression. 8 In parallel with advances in chemoimmunotherapy, elucidation of CLL B-cell biology has identified new therapeutic targets. 9 The interruption of leukemia proliferative signals mediated through the B-cell receptor appears to be one of the most promising approaches. [10] [11] [12] Major effects have been seen with ibrutinib, an irreversible inhibitor of Bruton's tyrosine kinase (BTK), a B-cell signaling protein involved in B-cell development, differentiation, proliferation, and survival. 10, 13 Ibrutinib was initially found to have durable efficacy in patients who had relapsed or refractory CLL. 13, 14 Subsequent phase 3 trials involving previously untreated patients with progressive CLL who were too frail to receive aggressive therapy showed superior progression-free survival and overall survival with ibrutinib as compared with chlorambucil, which led to approval of the drug by the Food and Drug Administration (FDA) as a first-line treatment option. 15 However, data regarding the efficacy of ibrutinib as a first-line treatment for patients 70 years of age or younger with CLL, as compared with the efficacious chemoimmunotherapy regimen of fludarabine-cyclophosphamide-rituximab, have been limited. We conducted a multicenter, openlabel, randomized, phase 3 trial (E1912) through the National Clinical Trials Network (NCTN) to evaluate the efficacy and safety of treatment with ibrutinib in combination with six cycles of rituximab, as compared with fludarabine-cyclophosphamide-rituximab, in previously untreated patients with CLL who were 70 years of age or younger.
Me thods

Trial Participants
Eligible participants were previously untreated patients with CLL or the small lymphocytic lymphoma (SLL) subtype of CLL who were 70 years of age or younger and who would be appropriate candidates for treatment according to the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) Working Group criteria (see the Supplementary Appendix, available with the full text of this article at NEJM.org). 16 Comprehensive eligibility criteria are listed in the Supplementary Appendix. Patients with chromosome 17p13 deletion were excluded from the trial because of the poor response of CLL in these patients to fludarabine-cyclophosphamide-rituximab therapy. 1, 3, 17 
Trial Oversight
This trial was designed and coordinated by the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN) Cancer Research Group in collaboration with the other NCTN Cooperative Groups. The trial protocol (available at NEJM.org) was approved by the National Cancer Institute (NCI) central institutional review board and local institutional review boards as required by participating institutions. The trial was conducted in accordance with the principles of the Declaration of Helsinki. Data that were gathered and analyzed by trial investigators were entered into an electronic database maintained by the ECOG-ACRIN Biostatistical and Operations Office. The trial was monitored twice annually by a standing data and safety monitoring board that included persons from both within and outside ECOG-ACRIN. The authors reviewed and approved the manuscript for submission for publication and vouch for the accuracy and completeness of the data and for the adherence of the trial to the protocol. Ibrutinib was provided by Pharmacyclics (a subsidiary of AbbVie) under a cooperative research and development agreement with the NCI.
Randomization and Treatment
After providing written informed consent, eligible participants underwent randomization, which was stratified according to the age of the patients (<60 years vs. 60 to 70 years), ECOG performance-status score (0 or 1 vs. ≥2; scores are on a 5-point scale, with higher numbers indicating greater disability), Rai stage (0 to II [low or intermediate risk] vs. III or IV [high risk]), and the presence or absence of chromosome 11q22.3 deletion on fluorescence in situ hybridization analysis. Patients were randomly assigned in a 2:1 ratio to receive either ibrutinib-rituximab or chemoimmunotherapy with fludarabine-cyclophosphamide-rituximab.
Patients who were randomly assigned to the ibrutinib-rituximab group received ibrutinib (at a dose of 420 mg per day until disease progression or an unacceptable level of side effects occurred) and rituximab (50 mg per square meter of body-surface area on day 1 of cycle 2; 325 mg per square meter on day 2 of cycle 2; and 500 mg per square meter on day 1 of cycles 3 through 7); each cycle was 28 days. Patients who were randomly assigned to the chemoimmunotherapy group received six cycles of intravenous fludarabine (at a dose of 25 mg per square meter) and cyclophosphamide (250 mg per square meter) on days 1 through 3 with rituximab (50 mg per square meter on day 1 of cycle 1; 325 mg per square meter on day 2 of cycle 1; and 500 mg per square meter on day 1 of cycles 2 through 6) every 28 days. Full treatment information, including instructions regarding dose delays and modifications, is provided in the Supplementary Appendix.
Prophylaxis against Pneumocystis jirovecii (trimethoprim-sulfamethoxazole or alternative) and herpes zoster (valacyclovir or alternative) was given to patients in each group for 1 year after treatment initiation. All patients received allopurinol (300 mg orally once daily) on days 1 through 14 of cycle 1. Patients treated with ibrutinib-rituximab also received allopurinol with treatment cycle 2 (the first cycle that included rituximab). Growth factor support was permitted per guidelines of the American Society of Clinical Oncology (see the Supplementary Appendix). 18
Assessments of Safety and Response
All adverse events were graded according to the NCI Common Toxicity Criteria, version 4. For the purposes of dose modification, adverse events involving platelet count and hemoglobin level were graded according to the IWCLL CLL Working Group grading scale (see the Supplementary Appendix). 16 Responses were graded according to the 2008 IWCLL Working Group criteria that were in effect at the start of the trial 16 along with the 2018 modification that included the category of complete response with incomplete bone marrow recovery 19 (see the Supplementary Appendix). Isolated treatment-related lymphocytosis in the absence of disease progression according to other criteria was not considered to indicate progression until a nadir lymphocyte count was achieved. 19, 20 Bone marrow biopsies were performed at enrollment and at 12 months to assess response, with central review by an expert hematopathologist (see the Supplementary Appendix). Computed tomographic (CT) scans of the chest, abdomen, and pelvis were performed in all patients at enrollment and at the evaluation for response at 12 months. Minimal residual disease (MRD) was assessed by means of peripheral-blood flow cytometry with a sensitivity greater than 1 CLL cell per 10,000 leukocytes (see the Supplementary Appendix). MRD assays were performed at the time of the 12-month response evaluation and at 24 and 36 months after randomization.
Statistical Analysis
The primary end point was progression-free survival, which was defined as the time from randomization to documented CLL progression or death without documented progression. Patients alive without documented progression had their data censored at the last disease assessment. The trial was designed to have 80% power to detect a hazard ratio for progression or death (in the analysis of progression-free survival) of 0.67 (ibrutinib-rituximab vs. chemoimmunotherapy) or less with the use of a stratified log-rank test at the one-sided alpha level of 2.5%. The planned enrollment was 519 patients, to be randomly assigned in a 2:1 ratio to receive ibrutinib-rituximab or chemoimmunotherapy.
With input from the FDA, interim analyses for progression-free survival were planned to start at 24 to 27 months after full enrollment and annually until either the efficacy boundary was crossed or full information (203 events of progression or death) was reached. The prespecified boundary for the first interim analysis of progression-free survival was 2.807 on the z-statistic scale, which corresponded to a onesided P value of 0.0025. A truncated version of the O'Brien-Fleming boundary was to be used subsequently. 21 Futility rules for harm and inefficacy were included (see the Supplementary Appendix).
Overall survival, which was defined as time from randomization to death from any cause, was a secondary end point and was to be tested only if the result in the progression-free survival analysis crossed the efficacy boundary. Patients who were alive had their data censored at the last date of contact. Interim analyses for overall survival were to start when the efficacy boundary for progression-free survival was crossed and to continue annually until early stopping criteria were met or full information (125 deaths) was reached. Critical values at each interim analysis were to be determined with the use of the truncated O'Brien-Fleming boundary.
Stratified log-rank tests 22 were used to compare time-to-event distributions. Hazard ratios were estimated with the use of stratified Cox proportional-hazards models. 23 The frequency of response and the incidence of adverse events were compared between the two groups with the use of Fisher's exact test. Descriptive statistics were used to summarize the characteristics of the patients. Time-to-event distributions were estimated with the use of the Kaplan-Meier method. The primary analysis was conducted in the intention-to-treat population, which included all the patients who had undergone randomization, regardless of eligibility or treatment status. P values are two-sided, and 95% confidence intervals are presented.
R esult s
Patients
From March 2014 through June 2016, the trial enrolled 529 patients (Table 1) . A total of 354 patients were assigned to the ibrutinib-rituximab group, and 175 to the chemoimmunotherapy group. A total of 19 patients did not start the protocol-specified therapy ( Fig. 1) .
At a median follow-up of 33.6 months, 279 of the 354 patients (78.8%) who had been randomly assigned to receive ibrutinib-rituximab continued ibrutinib therapy, and 132 of the 175 patients (75.4%) who had been randomly assigned to receive chemoimmunotherapy continued to be monitored. The mean number of treatment cycles among all the patients in the chemoimmunotherapy group who started therapy was five; 67.1% of these patients (106 of 158 patients) received six cycles. At the interim analysis, the median duration of treatment in the ibrutinibrituximab group was 33.0 months (range, 1.0 to 54.0); 16.8% of the patients discontinued therapy for reasons other than disease progression or death ( Table S10 in the Supplementary Appendix).
Efficacy
The first interim analysis was performed in September 2018. There were 77 events of progression or death and 14 deaths (8 without progression). The Kaplan-Meier estimates of progression-free survival and overall survival are shown in Figures  2A and 3 , respectively. At 3 years, the percentage of patients with progression-free survival was 89.4% (95% confidence interval [CI], 86.0 to 93.0) in the ibrutinib-rituximab group, as compared with 72.9% (95% CI, 65.3 to 81.3) in the chemoimmunotherapy group. The difference in progression-free survival crossed the prespecified boundary (hazard ratio for progression or death, 0.35; 95% CI, 0.22 to 0.56; P<0.001).
Overall survival was higher in the ibrutinibrituximab group than in the chemoimmunotherapy group (hazard ratio for death, 0.17; 95% CI, 0.05 to 0.54; P<0.001). Overall survival at 3 years was 98.8% (95% CI, 97.6 to 100) in the ibrutinib-rituximab group, as compared with 91.5% (95% CI, 86.2 to 97.0) in the chemoimmunotherapy group. Data regarding progressionfree survival and overall survival among eligible patients who started the assigned treatment are provided in the Supplementary Appendix.
In prespecified subgroup analyses of progression-free survival, ibrutinib-rituximab was superior to chemoimmunotherapy independent of age, sex, or Rai stage and was also superior to chemoimmunotherapy in the subgroup of patients with chromosome 11q22.3 deletion ( Fig. 2C ). Ibrutinib-rituximab resulted in superior progression-free survival, as compared with chemoimmunotherapy, at 3 years among patients with IGHVunmutated CLL (90.7% vs. 62.5%; hazard ratio for progression or death, 0.26; 95% CI, 0.14 to 0.50) ( Fig. 2B) . At the interim analysis, the difference in progression-free survival at 3 years * Plus-minus values are means ±SD. Patients were randomly assigned to receive ibrutinib-rituximab or chemoimmunotherapy with fludarabine-cyclophosphamide-rituximab. Data include patients with small lymphocytic lymphoma (SLL); overall, 11.4% of the patients (11.7% in the ibrutinib-rituximab group and 10.9% in the chemoimmunotherapy group) had the SLL subtype of chronic lymphocytic lymphoma. Percentages may not total 100 because of rounding. More detailed information regarding the characteristics of the patients at baseline is provided in Table S1 in the Supplementary Appendix. † Eastern Cooperative Oncology Group (ECOG) performance-status scores are assessed on a 5-point scale, with higher scores indicating greater disability. ‡ Two patients with chromosome 17p13 deletion were enrolled and randomly assigned to the ibrutinib-rituximab group but were later found to be ineligible on the basis of fluorescence in situ hybridization analysis. § Immunoglobulin heavy-chain variable region (IGHV) mutation status was tested in the 436 patients (82.4% of the overall population) who agreed to participate in the correlative study component of the trial and who provided a research sample. Among the 436 patients who underwent testing, IGHV status could be determined in 395. among patients with IGHV-mutated CLL was not significant (87.7% in the ibrutinib-rituximab group and 88.0% in the chemoimmunotherapy group; hazard ratio, 0.44; 95% CI, 0.14 to 1.36) ( Fig. S3A in the Supplementary Appendix).
The percentage of patients with an overall response as determined by physical examination was higher in the ibrutinib-rituximab group (95.8%; 95% CI, 93.1 to 97.6) than in the chemoimmunotherapy group (81.1%; 95% CI, 74.5 to 86.6). With the inclusion of CT scan results and central bone marrow review (when possible), the incidence of complete response with or without blood count normalization was lower in the ibrutinib-rituximab group (17.2%; 95% CI, 13.4 to 21.6) than in the chemoimmunotherapy group (30.3%; 95% CI, 23.6 to 37.7).
MRD in the peripheral blood at the 12-month response assessment was evaluated in 276 of 354 patients (78.0%) who were treated with ibrutinib-rituximab and in 103 of 175 patients (58.9%) who received chemoimmunotherapy with fludarabine-cyclophosphamide-rituximab. A lower percentage of patients who were treated with ibrutinib-rituximab (8.3%; 95% CI, 5.4 to 12.2) than with chemoimmunotherapy (59.2%; 95% CI, 49.1 to 68.8) were MRD-negative at cycle 12 (Fig. S1 in the Supplementary Appendix).
Safety
All adverse events of grade 3 or higher that were reported in more than 2% of the patients in either group are summarized in Table 2 . The incidence of adverse events of grade 3 or higher, independent of attribution, was similar in the two groups (in 282 of 352 patients [80.1%] treated with ibrutinib-rituximab and in 126 of 158 patients [79.7%] who received chemoimmu- All 529 patients who had been enrolled in the trial were included in the intention-to-treat analysis. Of the 529 patients who underwent randomization, 31 (5.9%) were determined to have not met the eligibility criteria and were excluded from the analysis of eligible patients who started assigned therapy (see the Supplementary Appendix). The safety analysis included 510 patients who started the assigned protocol therapy. GFR denotes glomerular filtration rate. There was a higher incidence of grade 3 or 4 hypertension in the ibrutinib-rituximab group than in the chemoimmunotherapy group (66 patients [18.8%] vs. 13 [8.2%], P = 0.002). Hemorrhagic events of grade 3 or higher occurred in 4 patients (1.1%) in the ibrutinib-rituximab group (all grade 3 events) but in no patients in the chemoimmunotherapy group (P = 0.32).
Cardiac toxic effects of grade 3 or higher occurred in 23 patients (6.5%) treated with ibrutinib-rituximab, including 13 cases of atrial fibrillation or atrial flutter, 3 cases of cardiac chest pain, 2 cases of supraventricular tachycardia, 2 cases of heart failure (nonfatal), 2 cases of pericardial effusion, 1 case of sinus bradycardia, 1 case of ventricular tachycardia, 1 case of cardiac arrest (nonfatal), and 1 case of myocardial infarction. Cardiac toxic effects of grade 3 or higher occurred in 3 patients who received chemoimmunotherapy with fludarabine-cyclophosphamide-rituximab, including 2 cases of atrial fibrillation and 1 case of acute coronary syndrome. Atrial fibrillation of any grade occurred in 26 patients (7.4%) receiving ibrutinib-rituximab and in 5 patients (3.2%) receiving chemoimmunotherapy. One patient in the ibrutinibrituximab group had atrial fibrillation at enrollment, which was exacerbated by ibrutinib during cycle 1; the patient had sudden death 21 days after the start of cycle 2 of ibrutinib-rituximab therapy. A detailed summary of all adverse events of grade 3 or higher that were attributed by the treating physician to trial treatment is provided in Table S7 in the Supplementary Appendix.
Causes of death are listed in Table S6 in the Supplementary Appendix. Among the 10 deaths in the chemoimmunotherapy group, the cause was CLL or therapy-related in the majority of patients (4 deaths due to CLL, 2 due to therapyrelated acute myeloid leukemia, 1 due to lung cancer, 1 due to metastatic colon cancer, 1 due to drug overdose, and 1 due to infection). Among the 4 deaths in the ibrutinib-rituximab group, the cause was CLL in the minority of patients (1 death due to CLL, 1 due to lung adenocarcinoma with respiratory failure, 1 due to acute respiratory failure, and 1 sudden death in a patient with history of atrial fibrillation).
Discussion
In this randomized trial involving patients 70 years of age or younger who had previously untreated CLL or SLL and did not have chromo-some 17p13 deletion, ibrutinib-rituximab treatment was superior to chemoimmunotherapy with fludarabine-cyclophosphamide-rituximab with respect to progression-free survival and overall survival. Chemoimmunotherapy led to a higher frequency of complete response and rendered more patients MRD-negative than did ibrutinibrituximab therapy. Nonetheless, the risk of pro- gression or death was 65% lower and the risk of death was 83% lower with ibrutinib-rituximab than with chemoimmunotherapy. The proportion of patients who had an adverse event of grade 3 or higher was similar in the two groups.
Since fludarabine-cyclophosphamide-rituximab is widely accepted as an effective chemoimmunotherapy regimen for patients with CLL, the improvements in both progression-free survival and overall survival that were observed with six cycles of ibrutinib-rituximab followed by continuous ibrutinib therapy, as compared with the 6-month course of chemoimmunotherapy, are notable. 1, [3] [4] [5] [6] [7] Three previous trials have shown a survival advantage with one therapy over another among patients with previously untreated CLL. 1, 2, 15 The advantage of six cycles of ibrutinib-rituximab followed by continuous ibrutinib therapy with regard to these end points exceeded the prespecified thresholds for superiority at the time of the first interim analysis, despite the fact that the progression-free survival and overall survival observed among patients treated with fludarabine-cyclophosphamide-rituximab was similar to or better than that anticipated on the basis of historical studies ( Table S9 in the Supplementary Appendix). 1, 3 Since the current advantage with regard to overall survival was based on a limited number of events, the long-term followup for survival among the patients in this trial, as well as for the incidence of myelodysplastic syndrome or acute myeloid leukemia, second cancers, and infectious complications, will be important.
Ibrutinib-rituximab resulted in superior progression-free survival in high-risk subgroups, including patients with Rai stage III or IV disease, chromosome 11q22.3 deletion, and unmutated IGHV. Chemoimmunotherapy with fludarabinecyclophosphamide-rituximab has proved to be particularly effective in patients with IGHV-mutated CLL, 5, 6 with roughly half the patients in this lower-risk subgroup remaining in remission 8 to 10 years after the initiation of treatment. 7 Longer follow-up in this subgroup of patients will provide additional clinical insights.
The safety results regarding ibrutinib-rituximab therapy in the E1912 trial were consistent with the results of previous trials of ibrutinibbased therapy. [13] [14] [15] The risk of atrial fibrillation of any grade was 7.4% in the ibrutinib-rituximab group. The recently reported Alliance 041202 trial, which tested first-line ibrutinib-rituximab therapy and ibrutinib monotherapy, showed that the incidence of atrial fibrillation in these two groups was 14% and 17%, respectively, among patients with CLL who were 65 years of age or older (median age, 71 years). 24 An age of 65 years or older, history of hypertension, and history of atrial fibrillation are risk factors for the development of atrial fibrillation during ibrutinib treatment, 25 which suggests that the lower incidence of cardiac complications in the E1912 trial may be due to the younger patient population (median age, 58 years) relative to a pooled analysis of patients participating in other trials (median age, 67 years). 25 Unexplained or unwitnessed death, which can be due to cardiac arrhythmias, was observed in only 1 patient in the E1912 trial, as compared with 11 of 361 patients (3%) treated with ibrutinib in the Alliance 041202 trial. 24 Grade 3 or 4 hypertension in patients who were treated with ibrutinib-rituximab in the E1912 trial also occurred at a lower frequency than that seen among patients in the Alliance 041202 trial (18.8% vs. 34%). 24 Major hemorrhagic events (all grade 3) occurred in 1.1% of the patients in the ibrutinib-rituximab group, with no fatal events. As of the interim analysis, one case of nonfatal cardiac arrest has been observed in the E1912 trial. Given the long-term, indefinite use of ibrutinib, we continue to monitor this end point closely.
The superior overall survival with ibrutinibbased therapy that was observed in the E1912 trial but not in the Alliance 041202 trial is notable because the chemoimmunotherapy that was used in the E1912 trial is more efficacious than the chemoimmunotherapy used in the Alliance trial. 3 Several possible factors may contribute to these findings. First, more efficacious therapy may contribute more to survival prospects in younger patients with CLL with fewer coexisting conditions, who are less likely than older patients to die from unrelated causes. Second, more severe treatment-related toxic effects, including an increased risk of sudden death among older patients, may offset decreases in disease-related mortality among older patients. The higher mortality among patients receiving active treatment in the Alliance trial (7% of patients treated with ibrutinib-rituximab) relative to the participants in the E1912 trial (1%) and reported outcomes in The New England Journal of Medicine
